Curis (CRIS) EBT Margin (2010 - 2025)
Curis' (CRIS) quarterly EBT Margin came in at 1700.88% in Q4 2025, up 198841.0% on a YoY basis from N/an in Q4 2024, and up 798.92% quarter-over-quarter from 243.36% in Q3 2025.
Powered by 
Analysis
Curis (CRIS) EBT Margin (2010 - 2025) Analysis & Trends
Curis (CRIS) has reported EBT Margin for 16 consecutive years, with 1700.88% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin rose 198841.0% year-over-year to 1700.88%; the trailing twelve-month figure through Jun 2026 stood at 224.69% (up 11656.0% YoY), and the FY2025 full-year result was 80.29%, up 31748.0% from the prior year.
- EBT Margin grew to 1700.88% in Q4 2025 per CRIS's latest filing, from 243.36% in the prior quarter.
- Across five years, EBT Margin topped out at 1700.88% in Q4 2025 and bottomed at 803.65% in Q1 2022.
- Historically, EBT Margin has averaged 348.76% across 5 years, with a median of 440.25% in 2021.
- The sharpest annual moves came in 2022 and 2025: EBT Margin plunged 35015 bps in 2022, then surged 198841 bps in 2025.
- Over 5 years, EBT Margin stood at 434.45% in 2021, then increased by 10 bps to 392.41% in 2022, then decreased by 11 bps to 434.42% in 2023, then surged by 34 bps to 287.53% in 2024, then jumped by 692 bps to 1700.88% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 1700.88%, 243.36%, and 312.59% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 4.84% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -2.67% |
| 10 | Curis | 2.63 Mn | -2.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1,700.88% |
| Sep 30, 2025 | -243.36% |
| Jun 30, 2025 | -312.59% |
| Mar 31, 2025 | -446.05% |
| Dec 31, 2024 | -287.53% |
| Sep 30, 2024 | -344.32% |
| Jun 30, 2024 | -463.59% |
| Mar 31, 2024 | -569.32% |
| Dec 31, 2023 | -434.42% |
| Sep 30, 2023 | -429.97% |
| Jun 30, 2023 | -544.42% |
| Mar 31, 2023 | -503.22% |
| Dec 31, 2022 | -392.41% |
| Sep 30, 2022 | -470.58% |
| Jun 30, 2022 | -666.11% |
| Mar 31, 2022 | -803.65% |
| Dec 31, 2021 | -434.45% |
| Sep 30, 2021 | -363.64% |
| Jun 30, 2021 | -513.04% |
| Mar 31, 2021 | -453.49% |